Several oral drugs have been developed in recent years for treatment of relapsing–remitting multiple sclerosis. Two large phase III trials have now clearly demonstrated the clinical efficacy and good safety profile of oral dimethyl fumarate (BG12)—an anti-inflammatory and cytoprotective agent—in patients with this disease.
This is a preview of subscription content, log in via an institution to check access.
References
Compston, A. & Coles, A. Multiple sclerosis. Lancet 372, 1502–1517 (2008).
Schweckendiek, W. Treatment of psoriasis vulgaris [German]. Med. Monatsschr. 13, 103–104 (1959).
Schimrigk, S. et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur. J. Neurol. 13, 604–610 (2006).
Kappos, L. et al. Efficacy and safety of oral fumarate in patients with relapsing–remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372, 1463–1472 (2008).
Gold, R. et al. Placebo-controlled phase 3 study of oral BG12 for relapsing multiple sclerosis. N. Engl. J. Med. 376, 1098–1107 (2012).
Fox, R. J. et al. Placebo-controlled phase 3 study of oral BG12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 376, 1087–1097 (2012).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Limmroth, V. Oral BG12 for treatment of relapsing–remitting MS. Nat Rev Neurol 9, 8–10 (2013). https://doi.org/10.1038/nrneurol.2012.231
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2012.231
- Springer Nature Limited